Table 3.
Baseline characteristics of 1095 colorectal cancer patients stratified by stage and tumor location
| Characteristic | Stage I | Stage II | Stage III | Stage IV | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Right-sided colon (%) | Left-sided colon (%) | P value | Right-sided colon (%) | Left-sided colon (%) | P value | Right-sided colon (%) | Left-sided colon (%) | P value | Right-sided colon (%) | Left-sided colon (%) | P value | |
| N = 28 (14.6 %) | N = 164 (85.3 %) | N = 101 (26.1 %) | N = 286 (73.9 %) | N = 80 (24.2 %) | N = 251 (75.8 %) | N = 40 (21.4 %) | N = 145 (78.4 %) | |||||
| Age (years, mean ± SD) | 67.36 ± 10.05 | 65.04 ± 13.20 | 0.289 | 65.90 ± 13.67 | 65.30 ± 12.15 | 0.678 | 61.99 ± 14.86 | 61.90 ± 13.21 | 0.959 | 66.70 ± 11.57 | 62.85 ± 12.77 | 0.087 |
| Gender | 0.603 | 0.244 | 0.751 | 0.011* | ||||||||
| Female | 12 (42.9) | 79 (48.2) | 52 (47.3) | 128 (40.9) | 37 (46.3) | 111 (44.2) | 23 (57.5) | 51 (35.2) | ||||
| Male | 16 (57.1) | 85 (51.8) | 58 (52.7) | 185 (59.1) | 43 (53.8) | 140 (55.8) | 17 (42.5) | 94 (64.8) | ||||
| Tumor size | 1.000 | 0.060 | 0.070 | 0.921 | ||||||||
| < 5 cm | 24 (85.7) | 139 (85.8) | 42 (41.6) | 150 (52.4) | 37 (46.3) | 144 (57.8) | 18 (46.2) | 62 (45.3) | ||||
| ≥ 5 cm | 4 (14.3) | 23 (14.2) | 59 (58.4) | 136 (47.6) | 43 (53.8) | 105 (42.2) | 21 (53.8) | 75 (54.7) | ||||
| Histology | 0.195 | 0.002* | 0.036* | 0.517 | ||||||||
| Well | 10 (35.7) | 32 (20.3) | 6 (6.1) | 11 (3.9) | 3 (3.9) | 5 (2.0) | 1 (2.6) | 3 (2.2) | ||||
| Moderately | 17 (60.7) | 120 (75.9) | 76 (76.8) | 255 (90.1) | 57 (74.0) | 212 (86.5) | 31 (79.5) | 117 (86.7) | ||||
| Poorly | 1 (3.6) | 6 (3.8) | 17 (17.2) | 17 (6.0) | 17 (22.1) | 28 (11.4) | 7 (17.9) | 15 (11.1) | ||||
| Tumor depth | 0.872 | 0.197 | 0.457 | 0.858 | ||||||||
| T1 | 10 (35.7) | 56 (34.1) | 0 (0.0) | 0 (0.0) | 2 (2.5) | 2 (0.8) | 0 (0.0) | 1 (0.7) | ||||
| T2 | 18 (64.3) | 108 (65.9) | 0 (0.0) | 0 (0.0) | 5 (6.3) | 25 (10.0) | 1 (2.6) | 6 (4.3) | ||||
| T3 | 0 (0.0) | 0 (0.0) | 101 (100.0) | 279 (97.6) | 67 (83.8) | 209 (83.3) | 31 (79.5) | 103 (74.1) | ||||
| T4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (2.4) | 6 (7.5) | 15 (6.0) | 7 (17.9) | 29 (20.9) | ||||
| Lymph Node metastasis | 0.158 | 0.813 | ||||||||||
| N0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 13 (33.3) | 41 (30.1) | ||||
| N1 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 49 (61.3) | 175 (69.7) | 13 (33.3) | 42 (30.9) | ||||
| N2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 31 (38.8) | 76 (30.3) | 13 (33.3) | 53 (39.0) | ||||
| Vascular invasion | 0.695 | 0.133 | 0.110 | 0.510 | ||||||||
| No | 27 (96.4) | 146 (92.4) | 83 (82.2) | 211 (74.8) | 39 (48.8) | 145 (58.9) | 14 (38.9) | 59 (45.0) | ||||
| Yes | 1 (3.6) | 12 (7.6) | 18 (17.8) | 71 (25.2) | 41 (51.2) | 101 (41.1) | 22 (61.1) | 72 (55.0) | ||||
| Perineural invasion | 0.473 | 0.861 | 0.512 | 0.790 | ||||||||
| No | 27 (96.4) | 143 (90.5) | 67 (66.3) | 185 (65.4) | 47 (59.5) | 136 (55.3) | 16 (42.1) | 52 (39.7) | ||||
| Yes | 1 (3.6) | 15 (9.5) | 34 (33.7) | 98 (34.6) | 32 (40.5) | 110 (44.7) | 22 (57.9) | 79 (60.3) | ||||
| Pre-op serum CEAa level | 0.560 | 0.237 | 0.043* | 0.410 | ||||||||
| < 5 ng/ml | 22 (81.5) | 127 (85.8) | 62 (62.6) | 150 (55.8) | 28 (38.4) | 122 (51.9) | 9 (25.0) | 25 (18.8) | ||||
| ≥ 5 ng/ml | 5 (18.5) | 21 (14.2) | 37 (37.4) | 119 (44.2) | 45 (61.6) | 113 (48.1) | 27 (75.0) | 108 (81.2) | ||||
| Post-op serum CEAa level | 0.697 | 0.158 | 0.025* | 0.764 | ||||||||
| < 5 ng/ml | 24 (96.0) | 140 (92.1) | 75 (79.8) | 232 (85.9) | 49 (64.5) | 185 (77.4) | 10 (27.0) | 37 (29.6) | ||||
| ≥ 5 ng/ml | 1 (4.0) | 12 (7.9) | 19 (20.2) | 38 (14.1) | 27 (35.5) | 54 (22.6) | 27 (73.0) | 88 (70.4) | ||||
| Pre-op serum Albumin level (g/dl) | 3.72 ± 0.37 | 3.76 ± 0.39 | 0.664 | 3.46 ± 0.47 | 3.58 ± 0.46 | 0.030 | 3.68 ± 0.37 | 3.69 ± 0.40 | 0.887 | 3.48 ± 0.45 | 3.46 ± 0.50 | 0.885 |
| Diabetes mellitus | 0.307 | 0.841 | 0.920 | 0.844 | ||||||||
| Yes | 9 (32.1) | 38 (23.2) | 24 (23.8) | 69 (24.1) | 19 (23.8) | 61 (24.3) | 8 (20.0) | 27 (18.6) | ||||
| No | 19 (67.9) | 126 (76.8) | 77 (76.2) | 217 (75.9) | 62 (76.2) | 190 (75.7) | 32 (80.0) | 118 (81.4) | ||||
| Chemotherapy | 0.030* | 0.852 | 0.817 | |||||||||
| Yes | 53 (52.5) | 185 (64.7) | 72 (91.1) | 227 (90.4) | 33(82.6) | 121 (84.0) | ||||||
| No | 48 (47.5) | 101 (35.3) | 7 (8.9) | 24 (9.6) | 7 (17.5) | 23 (16.0) | ||||||
| Cardiac disease | 0.257 | 0.365 | 0.772 | 0.976 | ||||||||
| Yes | 15 (53.6) | 69 (42.1) | 41 (40.6) | 131 (45.8) | 32 (40.0) | 105 (41.8) | 15 (37.5) | 54 (37.2) | ||||
| No | 13 (46.4) | 95 (57.9) | 60 (59.4) | 156 (54.2) | 48 (60.0) | 146 (58.2) | 25 (62.5) | 91 (62.8) | ||||
| Renal disease | 0.127* | 0.693 | 0.450 | 1.000 | ||||||||
| Yes | 3 (10.7) | 6 (3.7) | 6 (5.9) | 14 (4.9) | 2 (2.5) | 11 (4.4) | 2 (5.0) | 8 (5.5) | ||||
| No | 25 (89.3) | 158 (96.3) | 95 (94.1) | 272 (95.1) | 78 (97.5) | 240 (95.6) | 38 (95.0) | 137 (94.5) | ||||
| BMIb | 23.94 ± 3.88 | 23.70 ± 3.73 | 0.748 | 23.80 ± 4.39 | 23.73 ± 3.73 | 0.092 | 23.71 ± 4.13 | 23.95 ± 3.44 | 0.616 | 22.23 ± 4.31 | 22.77 ± 3.50 | 0.418 |
aCEA Carcinoembryonic antigen, bBMI Body mass index, *Indicated P < 0.05